Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human Immunodeficiency Virus Type 1 Group-Specific Antigen Gag Polyprotein (Gag)
- Target
- Gag
- Molecular classification
- Viral structural protein, Polyprotein
01
Overview
The Human Immunodeficiency Virus type 1 (HIV-1) group-specific antigen (Gag) polyprotein is a major structural protein essential for the assembly, budding, and release of HIV-1 virions from infected cells. The Gag polyprotein is encoded by the gag gene and is translated as a single precursor that undergoes proteolytic cleavage to yield several mature proteins critical for viral structure and function. These include Matrix protein (MA), Capsid protein (CA), Nucleocapsid protein (NC), Spacer peptides p1 and p2 and p6 protein. Each cleaved domain carries out distinct roles which allows the correct viral particle to form and be infectious. Mutations or failed processing disrupt these processes, leading to defective or noninfectious viruses.
- Other names
- HIV-1 GagGag polyproteinGroup-specific antigen
02
Mechanism of action
Protease inhibitors prevent the cleavage of Gag polyprotein, resulting in non-infectious viral particles.
03
Biological functions
Viral assemblyViral buddingGenome packagingMembrane binding
04
Disease associations
HIV-1 infectionAIDS pathogenesis
05
Safety considerations
Drug resistance mutations in Gag can emerge under selective pressure from protease inhibitors.
06
Interacting drugs
Protease inhibitors (e.g., Darunavir, Atazanavir, Ritonavir)
Beyond the preview
Go deeper on Human Immunodeficiency Virus Type 1 Group-Specific Antigen Gag Polyprotein (Gag).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Human Immunodeficiency Virus Type 1 Group-Specific Antigen Gag Polyprotein (Gag).